Oppenheimer bullish on VistaGen; shares up 62% [Seeking Alpha]
VistaGen Therapeutics, Inc. (VTGN)
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vistagen.com
Company Research
Source: Seeking Alpha
Oppenheimer bullish on VistaGen; shares up 62%Thinly traded nano cap VistaGen Therapeutics (VTGN+61.9%) is up on a whopping 53x surge in volume in apparent response to a bullish call by Oppenheimer's Jay Olsen (Outperform/$6) who says lead antidepressant candidate AV-101 should be a big winner considering its ketamine-like efficacy with less side effects.Topline data from its first Phase 2 study should be available by year-end. A data readout from a larger Phase 2,ELEVATE, is expected by mid-2019.AV-101 is an NMDA receptor antagonist, what the company says is a next-generation approach to treating major depressive disorder (MDD). Shares had been mired in a long-term downtrend, losing about 80% of their value since 2016, before today's action. Last month, shares sold off after the publication of a study on esketamine, also an NMDA receptor antagonist, that showed mixed results in MDD patients.Previously:Vistagen down 11% on mixed esketamine data(April 20)See all stocks on the move »Now
Show less
Read more
Impact Snapshot
Event Time:
VTGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTGN alerts
High impacting VistaGen Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VTGN
News
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) ConferenceBusiness Wire
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2Business Wire
- Vistagen Therapeutics: Initial Analysis Of Fasedienol Points To Bullish [Seeking Alpha]Seeking Alpha
- Why VistaGen Therapeutics Is A Buy: Fasedienol Potential For Anxiety Treatments [Seeking Alpha]Seeking Alpha
- Vistagen to Present at Stifel 2024 Virtual CNS DaysBusiness Wire
VTGN
Earnings
- 2/13/24 - Beat
VTGN
Sec Filings
- 4/16/24 - Form DEF
- 4/5/24 - Form PRE
- 4/1/24 - Form 8-K
- VTGN's page on the SEC website